AU2014250614B2 — A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
Assigned to Alpharma Pharmaceuticals LLC · Expires 2016-11-10 · 10y expired
What this patent protects
The present invention relates to abuse-resistant, sustained-release dosage forms comprising opioids , and provides for sequestering subunits comprising an antagonist and an agonist. The subunit comprise of an antagonist in a first layer and an agonist in a second layer, upon said…
USPTO Abstract
The present invention relates to abuse-resistant, sustained-release dosage forms comprising opioids , and provides for sequestering subunits comprising an antagonist and an agonist. The subunit comprise of an antagonist in a first layer and an agonist in a second layer, upon said first layer such that the antagonist is substantially sequestered when administered to a human being in an intact form, such that physical disruption of the dosage form decreases the euphoric effect of the agonist when administered to a person as compared to an immediate release agonist composition. In a preferred embodiment, the agonist is morphine, and the antagonist is naltrexone. Pharmaceutical compositions comprising said subunit are also provided. WO 2009/032270 PCT/US2008/010357 6 ----- -------- 0 0 0.5 1 1.5 2 3 4 6 8 MORPHINE -- WHOLE CRUSHED --------- PLACEBO
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.